GleamWall
中文EN

OCUL OCULAR THERAPEUTIX, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1393434 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.7%
TTM net income YoY-30.9%
TTM EPS YoY-0.7%
Revenue 3-yr CAGR-4.4%
Net income 3-yr CAGR—

Margins

Gross margin87.3%
Operating margin-680.9%
Net margin-648.6%
FCF margin-530.0%
EBITDA margin-667.4%

Returns

ROE-93.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.10x

Leverage & solvency

Liabilities / assets27.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage-30.59x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue27.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$12.87M$13.47M$10.79M$13.25M$14.54M$13.46M$10.70M$17.08M
Cost of revenue$1.46M$2.01M$1.33M$1.59M$1.77M$1.94M$1.26M$1.23M
Gross profit$11.42M$11.46M$9.46M$11.66M$12.77M$11.52M$9.44M$15.85M
R&D expense$74.79M$54.14M$66.21M$50.80M$52.36M$51.08M$42.86M$40.99M
SG&A expense$18.83M$22.16M$20.01M$17.66M$16.02M$14.35M$16.35M$14.60M
Operating income-$97.86M-$82.11M-$93.34M-$69.76M-$68.70M-$67.64M-$63.92M-$50.58M
Interest expense$2.81M$2.79M$2.78M$2.83M$3.00M$3.02M$2.98M$3.11M
Net income-$94.78M-$78.76M-$88.61M-$64.65M-$69.42M-$67.81M-$64.05M-$48.39M
EBITDA-$95.43M-$80.26M-$92.06M-$68.51M-$67.63M-$66.61M-$62.94M-$49.62M
EPS (basic)-0.42-0.35-0.40—-0.38-0.39-0.38—
EPS (diluted)-0.42-0.35-0.40—-0.38-0.39-0.38—
Weighted avg. shares (diluted)225.52M224.95M224.10M—183.92M172.59M169.40M—
Balance sheet
Cash & equivalents$530.61M$598.64M$666.70M$737.06M$344.77M$391.13M$349.68M$393.72M
Receivables$31.39M$30.26M$24.35M$30.65M$30.77M$30.41M$25.22M$32.39M
Inventory$4.26M$3.83M$3.74M$3.56M$3.49M$3.04M$3.27M$3.04M
Current assets$574.60M$644.43M$706.00M$782.13M$386.98M$433.38M$387.69M$440.99M
PP&E, net$20.28M$19.46M$18.43M$19.68M$16.95M$10.46M$10.78M$9.39M
Total assets$605.65M$671.32M$732.53M$808.06M$410.88M$451.33M$405.92M$457.94M
Current liabilities$63.02M$49.17M$47.68M$50.81M$49.29M$42.93M$37.93M$41.35M
Total liabilities$164.70M$151.28M$150.96M$153.75M$152.65M$145.42M$139.99M$142.59M
Shareholders' equity$440.95M$520.04M$581.57M$654.31M$258.23M$305.92M$265.93M$315.34M
Shares outstanding219.88M219.59M218.90M215.93M174.95M172.93M159.26M157.75M
Cash flow statement
Operating cash flow-$65.62M-$67.27M-$65.99M-$54.25M-$50.73M-$55.24M-$44.67M-$39.43M
Capital expenditure$3.03M$3.37M$4.66M$2.84M$5.99M$1.25M$1.93M$202,000
Free cash flow-$68.65M-$70.64M-$70.66M-$57.09M-$56.72M-$56.48M-$46.60M-$39.63M
Investing cash flow-$3.03M-$3.37M-$4.66M-$2.84M-$5.99M-$1.11M-$1.93M-$202,000
Financing cash flow$624,000$2.58M$294,000$449.38M$10.36M$97.81M$4.18M$4.51M
Depreciation & amortization$2.43M$1.85M$1.28M$1.25M$1.07M$1.03M$981,000$951,000
Stock-based compensation$15.07M$14.65M$15.58M$11.36M$11.69M$9.68M$10.46M$7.20M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.